ArticlePharmaceutical research2008
Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.
Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 102 citations in OpenAlex.
- Mechanism-based classification of in vitro-in vivo correlation failures and model-informed strategies for drug product development.Archives of pharmacal research · 2026Review
- The expanding role of formulations to enable oral delivery of poorly water-soluble drugs.Nature reviews. Drug discovery · 2026Review
- Improving In Vitro-In Vivo Correlation (IVIVC) for Lipid-Based Formulations: Overcoming Challenges and Exploring Opportunities.Pharmaceutics · 2025Review
- Prediction of Oral Drug Absorption in Rats from In Vitro Data.Pharmaceutical research · 2023Article
- Review
- Estimating the Oral Absorption from Self-Nanoemulsifying Drug Delivery Systems Using an In Vitro Lipolysis-Permeation Method.Pharmaceutics · 2021Article
- Self-Nano-Emulsifying Drug-Delivery Systems: From the Development to the Current Applications and Challenges in Oral Drug Delivery.Pharmaceutics · 2020Review
- The Effects of Dose Volume and Excipient Dose on Luminal Concentration and Oral Drug Absorption.The AAPS journal · 2020Review
- Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats.Pharmaceutical research · 2020Article
- New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.Pharmaceutical research · 2019Article
- Palm Oil in Lipid-Based Formulations and Drug Delivery Systems.Biomolecules · 2019Review
- Exploring the utility of the Chasing Principle: influence of drug-free SNEDDS composition on solubilization of carvedilol, cinnarizine and R3040 in aqueous suspension.Acta pharmaceutica Sinica. B · 2019Article
- Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens: in vivo and in vitro evaluations.The AAPS journal · 2017Article
- Evaluation of Pharmacokinetics, and Bioavailability of Higher Doses of Tocotrienols in Healthy Fed Humans.Journal of clinical & experimental cardiology · 2016Article
- Enhanced solubility and oral bioavailability of γ-tocotrienol using a self-emulsifying drug delivery system (SEDDS).Lipids · 2014Article
- In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.The AAPS journal · 2014Article
- Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis.Pharmaceutical research · 2013Article
- Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs.Journal of pharmaceutical sciences · 2013Article
- Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilic molecules: in vivo and in vitro studies.The AAPS journal · 2013Article
- SNEDDS Containing Poorly Water Soluble Cinnarizine; Development and in Vitro Characterization of Dispersion, Digestion and Solubilization.Pharmaceutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the use of Labrafil M2125CS as a lipid vehicle for danazol. Further, the possibility of predicting the in vivo behavior with a dynamic in vitro lipolysis model was evaluated.
methodsDanazol (28 mg/kg) was administered orally to rats in four formulations: an aqueous suspension, two suspensions in Labrafil M2125CS (1 and 2 ml/kg) and a solution in Labrafil M2125CS (4 ml/kg).
resultsThe obtained absolute bioavailabilities of danazol were 1.5 +/- 0.8%; 7.1 +/- 0.6%; 13.6 +/- 1.4% and 13.3 +/- 3.4% for the aqueous suspension, 1, 2 and 4 ml Labrafil M2125CS per kg respectively. Thus administration of danazol with Labrafil M2125CS resulted in up to a ninefold increase in the bioavailability, and the bioavailability was dependent on the Labrafil M2125CS dose. In vitro lipolysis of the formulations was able to predict the rank order of the bioavailability from the formulations, but not the absorption profile of the in vivo study.
conclusionsThe bioavailability of danazol increased when Labrafil M2125CS was used as a vehicle, both when danazol was suspended and solubilized in the vehicle. The dynamic in vitro lipolysis model could be used to rank the bioavailabilities of the in vivo data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.